Viewing Protocol Section

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT04624204
Ignite Creation Date: 2024-05-06 @ 3:24 PM
Last Modification Date: 2024-10-26 @ 1:49 PM
Study NCT ID: NCT04624204
Protocol Section: NCT04624204
Start Identification Module Data
Expand Identification Module Data
Brief Title: Placebo-controlled Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer LS-SCLC MK 7339-013KEYLYNK-013
Official Title: A Randomized Double-blind Placebo-controlled Phase 3 Study of Pembrolizumab MK-3475 in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib MK-7339 Compared to Concurrent Chemoradiation Therapy Alone in Participants With Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer LS-SCLC
Acronym: None
Organization: Merck Sharp Dohme LLC
Organization Class: INDUSTRY
Organization Study ID: 7339-013
Secondary IDs
Secondary ID Type Domain Link
MK-7339-013 OTHER None None
jRCT2031200296 REGISTRY None None
2019-003616-31 EUDRACT_NUMBER jRCT None
Start Status Module Data
Status Verified Date: 2024-08
Overall Status: ACTIVE_NOT_RECRUITING
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Merck Sharp Dohme LLC
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Merck Sharp Dohme LLC
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload